The group's principal activity is to study, manufacture and market pharmaceutical products based on multispecies, natural source alpha interferon. The main product of the group is alferon n injection(R) used in the treatment of refractory or recurring external genital warts. The group's alferon n injection(R) product has been approved by the United States food and drug administration for the treatment of genital warts. The group has also developed alferon n gel and alferon ldo(r). Alferon n gel is a topical, natural alpha interferon, which has potential use in the treatment of cervical dysphasia, intravaginal warts, mucocutaneous and genital herpes. Alferon ldo is a oral liquid natural alpha interferon which has potential use in the treatment of HIV-infected patients.
